Sodium Valproate a Histone Deacetylase Inhibitor Is Associated With Reduced Stroke Risk After Previous Ischemic Stroke or Transient Ischemic Attack

摘要

Background and Purpose—A variant in the histone deacetylase 9 (HDAC9) gene is associated with large artery stroke. Therefore, inhibiting HDAC9 might offer a novel secondary preventative treatment for ischemic stroke. The antiepileptic drug sodium valproate (SVA) is a nonspecific inhibitor of HDAC9. We tested whether SVA therapy given after ischemic stroke was associated with reduced recurrent stroke rate.